Adjuvant-dependent Immune Response to Malarial Transmission-blocking Vaccine Candidate Antigens

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1992 Nov 1

PMID 1383389

Citations 12

Authors

D J Rawlings

D C Kaslow

Affiliations

Soon will be listed here.

Abstract

Immune responses in major histocompatibility complex (MHC)-disparate congenic mouse strains immunized with sexual stage malaria parasites or purified recombinant protein were adjuvant dependent. Whereas mice exhibited a limited antibody response to immunization with newly emerged Plasmodium falciparum gametes in Freund's adjuvant, all five congenic mouse strains responded to several transmission-blocking vaccine candidate antigens, when parasites were emulsified in a monophosphoryl lipid A (MPL) and trehalose dimycolate (TDM) adjuvant. The humoral response in those animals immunized with the antigen in a MPL/TDM adjuvant was helper T cell dependent, as evident by boosting of the antibody response after a second immunization. If the immunogen consisted of purified recombinant protein, then the immune response was not MHC class II limited in mice immunized with either complete Freund's adjuvant or TDM/MPL. The potential role of adjuvants in overcoming apparent immune nonresponsiveness and the implications for development of a malaria transmission-blocking vaccine are discussed.

Citing Articles

Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.

Tifrea D, Pal S, Le Bon C, Cocco M, Zoonens M, de la Maza L Vaccine. 2020; 38(28):4412-4422.

PMID: 32386746 PMC: 8846571. DOI: 10.1016/j.vaccine.2020.04.065.

Complete Freund's adjuvant induces experimental autoimmune myocarditis by enhancing IL-6 production during initiation of the immune response.

Fontes J, Barin J, Talor M, Stickel N, Schaub J, Rose N Immun Inflamm Dis. 2017; 5(2):163-176.

PMID: 28474508 PMC: 5418134. DOI: 10.1002/iid3.155.

STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity.

Varikuti S, Oghumu S, Natarajan G, Kimble J, Sperling R, Moretti E Int Immunol. 2016; 28(11):565-570.

PMID: 27578456 PMC: 6018885. DOI: 10.1093/intimm/dxw038.

Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Bergmann-Leitner E, Leitner W Vaccines (Basel). 2015; 2(2):252-96.

PMID: 26344620 PMC: 4494256. DOI: 10.3390/vaccines2020252.

Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.

Kusi K, Faber B, Riasat V, Thomas A, Kocken C, Remarque E PLoS One. 2010; 5(11):e15391.

PMID: 21082025 PMC: 2972715. DOI: 10.1371/journal.pone.0015391.

References

Nijhout M . Plasmodium gallinaceum: exflagellation stimulated by a mosquito factor. Exp Parasitol. 1979; 48(1):75-80. DOI: 10.1016/0014-4894(79)90056-0. View

Ifediba T, Vanderberg J . Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature. 1981; 294(5839):364-6. DOI: 10.1038/294364a0. View

Hui G, Chang S, Gibson H, Hashimoto A, HASHIRO C, Barr P . Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. J Immunol. 1991; 147(11):3935-41. View

Good M, Berzofsky J, Maloy W, Hayashi Y, Fujii N, Hockmeyer W . Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. J Exp Med. 1986; 164(2):655-60. PMC: 2188237. DOI: 10.1084/jem.164.2.655. View

Kabilan L, Troye-Blomberg M, Perlmann H, Andersson G, Hogh B, Petersen E . T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine. Proc Natl Acad Sci U S A. 1988; 85(15):5659-63. PMC: 281819. DOI: 10.1073/pnas.85.15.5659. View

Graves P, Bhatia K, Burkot T, Prasad M, Wirtz R, Beckers P . Association between HLA type and antibody response to malaria sporozoite and gametocyte epitopes is not evident in immune Papua New Guineans. Clin Exp Immunol. 1989; 78(3):418-23. PMC: 1534822. View

Quakyi I, Otoo L, Pombo D, Sugars L, Menon A, De Groot A . Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens. Am J Trop Med Hyg. 1989; 41(2):125-34. View

Baker P, Fauntleroy M, STASHAK P, Hiernaux J, Cantrell J, Rudbach J . Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide. Infect Immun. 1989; 57(3):912-7. PMC: 313198. DOI: 10.1128/iai.57.3.912-917.1989. View

Good M, MILLER L, Kumar S, Quakyi I, Keister D, Adams J . Limited immunological recognition of critical malaria vaccine candidate antigens. Science. 1988; 242(4878):574-7. DOI: 10.1126/science.2902690. View

10.

Good M, Pombo D, LUNDE M, Maloy W, Halenbeck R, Koths K . Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2. J Immunol. 1988; 141(3):972-7. View

11.

Graves P, Carter R, Burkot T, Quakyi I, Kumar N . Antibodies to Plasmodium falciparum gamete surface antigens in Papua New Guinea sera. Parasite Immunol. 1988; 10(2):209-18. DOI: 10.1111/j.1365-3024.1988.tb00215.x. View

12.

Lemaire G, Tenu J, PETIT J, Lederer E . Natural and synthetic trehalose diesters as immunomodulators. Med Res Rev. 1986; 6(3):243-74. DOI: 10.1002/med.2610060302. View

13.

Azuma I, Ribi E, Meyer T, Zbar B . Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst. 1974; 52(1):95-101. DOI: 10.1093/jnci/52.1.95. View

14.

Ribi E . Beneficial modification of the endotoxin molecule. J Biol Response Mod. 1984; 3(1):1-9. View

15.

Rickman L, Gordon D, WISTAR Jr R, Krzych U, Gross M, Hollingdale M . Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991; 337(8748):998-1001. DOI: 10.1016/0140-6736(91)92659-p. View

16.

Kaslow D . Immunogenicity of Plasmodium falciparum sexual stage antigens: implications for the design of a transmission blocking vaccine. Immunol Lett. 1990; 25(1-3):83-6. DOI: 10.1016/0165-2478(90)90096-9. View

17.

Rawlings D, Kaslow D . A novel 40-kDa membrane-associated EF-hand calcium-binding protein in Plasmodium falciparum. J Biol Chem. 1992; 267(6):3976-82. View

18.

Hui G, Tam L, Chang S, Case S, HASHIRO C, Siddiqui W . Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195. Infect Immun. 1991; 59(5):1585-91. PMC: 257888. DOI: 10.1128/iai.59.5.1585-1591.1991. View

19.

de la Cruz V, Lal A, McCutchan T . Sequence variation in putative functional domains of the circumsporozoite protein of Plasmodium falciparum. Implications for vaccine development. J Biol Chem. 1987; 262(25):11935-9. View

20.

Carter R, Kumar N, Quakyi I, Good M, Mendis K, Graves P . Immunity to sexual stages of malaria parasites. Prog Allergy. 1988; 41:193-214. View